We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Mylan IRE Healthcare Limited

Unit 35/36, Grange Parade, Baldoyle Industrial Estate, Dublin 13, Ireland
Medical Information Direct Line: +44 (0)1707 853000 press 1
Medical Information e-mail: info@mylan.co.uk

Summary of Product Characteristics last updated on medicines.ie: 7/5/2017
SPC Creon 40000 Gastro-resistant Capsules

Go to top of the page

Creon 40000 Gastro-resistant Capsules

Go to top of the page

Each capsule contains 400 mg pancreatin equivalent to:



PhEur units



PhEur units



PhEur units

Produced from porcine pancreatic tissue.

For a full list of excipients, see 6.1.

Go to top of the page

Gastro-resistant capsule, hard.

Brown/clear Size 00 hard gelatin capsule containing light brown, gastro-resistant granules.

Go to top of the page

Go to top of the page
4.1 Therapeutic indications

For the treatment of pancreatic exocrine insufficiency.

Go to top of the page
4.2 Posology and method of administration

Adults (including the elderly) and children:

Creon 40000 should only be used if the patient requires equal to or more than 40,000 lipase units per meal or snack.

Initially one or two capsules during or immediately after meals. The capsules should be swallowed whole, without crushing or chewing, with enough fluid during or after each meal or snack. Dose adjustments, if required, should be done slowly, with careful monitoring of response and symptomatology.

When swallowing of capsules is difficult (e.g. small children or elderly patients), the capsules may be carefully opened and the minimicrospheres added to acidic soft food [pH < 5.5] that does not require chewing, or the minimicrospheres will be taken with acidic liquid [pH < 5.5].

This could be apple sauce or yoghurt or fruit juice with a pH less than 5.5, e.g. apple, orange or pineapple juice. This mixture should not be stored. Crushing and chewing of the minimicrospheres or mixing with food or fluid with a pH greater than 5.5 can disrupt the protective enteric coating. This can result in the early release of enzymes in the oral cavity and may lead to reduced efficacy and irritation of the mucous membranes. Care should be taken that no product is retained in the mouth.

It is important to ensure adequate hydration of patients at all times whilst dosing Creon 40000.

Colonic damage has been reported in patients with cystic fibrosis taking in excess of 10,000 units of lipase/kg/day (see section 4.8).

Go to top of the page
4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Go to top of the page
4.4 Special warnings and precautions for use

Strictures of the ileo-caecum and large bowel (fibrosing colonopathy) have been reported in patients with cystic fibrosis taking high doses of pancreatin preparations. As a precaution, unusual abdominal symptoms or changes in abdominal symptoms should be medically assessed to exclude the possibility of fibrosing colonopathy, especially if the patient is taking in excess of 10000 units of lipase/kg/day.

Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

4.6 Fertility, pregnancy and lactation

Fertility and pregnancy

For pancreatic enzymes no clinical data on exposed pregnancies are available.

Animal studies show no evidence for any absorption of porcine pancreatic enzymes. Therefore, no reproductive or developmental toxicity is to be expected.

Caution should be exercised when prescribing to pregnant women.


No effects on the breast-fed new-borns/infants are anticipated since animal studies suggest no systemic exposure of the breast-feeding woman to pancreatic enzymes. Pancreatic enzymes can be used during breast-feeding.

If required during pregnancy or lactation Creon should be used in doses sufficient to provide adequate nutritional status.

Go to top of the page
4.7 Effects on ability to drive and use machines

Creon has no or negligible influence on the ability to drive and use machines.

Go to top of the page
4.8 Undesirable effects

In clinical trials, more than 900 patients were exposed to Creon.

The most commonly reported adverse reactions were gastrointestinal disorders and were primarily mild or moderate in severity.

The following adverse reactions have been observed during clinical trials with the below indicated frequencies.

Organ system

Very common

≥ 1/10


≥ 1/100 to < 1/10


≥ 1/1000 to < 1/100

Frequency not known

Gastrointestinal disorders

abdominal pain*

nausea, vomiting, constipation, abdominal distention, diarrhoea*

strictures of the ileo-caecum and large bowel (fibrosing colonopathy)

Skin and subcutaneous tissue disorders


pruritus, urticaria

Immune system disorders

hypersensitivity (anaphylactic reactions).

*Gastrointestinal disorders are mainly associated with the underlying disease. Similar or lower incidences compared to placebo were reported for abdominal pain and diarrhoea.

Strictures of the ileo-caecum and large bowel (fibrosing colonopathy) have been reported in patients with cystic fibrosis taking high doses of pancreatin preparations, see section 4.4 Special warnings and precautions for use.

Allergic reactions mainly but not exclusively limited to the skin have been observed and identified as adverse reactions during postapproval use. Because these reactions were reported spontaneously from a population of uncertain size, it is not possible to reliably estimate their frequency.

Paediatric population

No specific adverse reactions were identified in the paediatric population. Frequency, type and severity of adverse reactions were similar in children with cystic fibrosis as compared to adults.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; e-mail: medsafety@hpra.ie

Go to top of the page
4.9 Overdose

Extremely high doses of pancreatin have been reported to be associated with hyperuricosuria and hyperuricaemia.

Supportive measures including stopping enzyme therapy and ensuring adequate rehydration are recommended.

Go to top of the page

Go to top of the page
5.1 Pharmacodynamic properties

Multienzymes (amylase, lipase, protease), ATC code: A09A A02

Creon contains porcine pancreatin formulated as enteric-coated (acid-resistant) minimicrospheres within gelatin capsules.

The capsules dissolve rapidly in the stomach releasing plenty of minimicrospheres, a multi-dose principle which is designed to achieve good mixing with the chyme, emptying from the stomach together with the chyme and after release, good distribution of enzymes within the chyme.

When the minimicrospheres reach the small intestine the coating rapidly disintegrates (at pH > 5.5) to release enzymes with lipolytic, amylolytic and proteolytic activity to ensure the digestion of fats, starches and proteins. The products of pancreatic digestion are then either absorbed directly, or following further hydrolysis by intestinal enzymes.

Clinical efficacy:

Overall 30 studies investigating the efficacy of Creon (Creon capsules with 10000, 25000 or 40000 Ph. Eur units of lipase and Creon 5000) in patients with pancreatic exocrine insufficiency have been conducted. Ten of these were placebo controlled studies performed in patients with cystic fibrosis, chronic pancreatitis or post surgical conditions.

In all randomized, placebo-controlled, efficacy studies, the pre-defined primary objective was to show superiority of Creon over placebo on the primary efficacy parameter, the coefficient of fat absorption (CFA).

The coefficient of fat absorption determines the percentage of fat that is absorbed into the body taking into account fat intake and fecal fat excretion. In the placebo-controlled PEI studies, the mean CFA (%) was higher with Creon treatment (83.0%) as compared to placebo (62.6%). In all studies, irrespective of the design, the mean CFA (%) at the end of the treatment period with Creon was similar to the mean CFA values for Creon in the placebo controlled studies.

Treatment with Creon improves the symptoms of pancreatic exocrine insufficiency including stool consistency, abdominal pain, flatulence and stool frequency, independent of the underlying disease.

Paediatric population

In cystic fibrosis (CF) the efficacy of Creon was demonstrated in 288 paediatric patients covering an age range from newborns to adolescents. In all studies, the mean end-of-treatment CFA values exceeded 80% on Creon comparably in all paediatric age groups.


Go to top of the page
5.2 Pharmacokinetic properties

Pharmacokinetic data are not available as the enzymes act locally in the gastro-intestinal tract. After exerting their action, the enzymes are digested themselves in the intestine.

Go to top of the page
5.3 Preclinical safety data

Preclinical data show no relevant acute, subchronic or chronic toxicity. Studies on genotoxicity, carcinogenicity or toxicity to reproduction have not been performed.

Go to top of the page

Go to top of the page
6.1 List of excipient(s)


Macrogol 4000

Cetyl alcohol

Triethyl citrate

Hypromellose phthalate




Iron oxide (E172)

Titanium dioxide (E171)

Sodium lauryl sulphate

Go to top of the page
6.2 Incompatibilities

Not applicable.

Go to top of the page
6.3 Shelf life

2 years.

Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C.

Keep container tightly closed in order to protect from moisture.

Go to top of the page
6.5 Nature and contents of container

HDPE tablet container with polypropylene closure, containing 50 or 100 capsules.

Not all pack sizes may be marketed.

Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.

Go to top of the page

Mylan IRE Healthcare Limited,

Unit 35/36,

Grange Parade,

Baldoyle Industrial Estate,

Dublin 13,


Go to top of the page

PA 2010/8/3

Go to top of the page

Date of first authorisation: 8th September 2006

Date of last renewal: 8th September 2011

Go to top of the page

June 2017

Link to this document from your website:

Document Links

  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients